胰岛素泵治疗后转换为德谷胰岛素利拉鲁肽注射液治疗病例分享  

Case Reports:Switch from Insulin Pump Therapy to Insulin Degludec and Liraglutide Injection

作　　者：林文简 洪天配[2] LIN Wenjian;HONG Tianpei(The First Affiliated Hospital of Harbin Medical University,Harbin Heilongjiang 150000,China;The Third Hospital of Peking University,Beijing 100191,China)

机构地区：[1]哈尔滨医科大学附属第一医院,黑龙江哈尔滨150000 [2]北京大学第三医院,北京100191

出　　处：《药品评价》2023年第6期701-705,共5页Drug Evaluation

摘　　要：回顾性总结哈尔滨医科大学附属第一医院内分泌科4例由胰岛素泵胰岛素强化治疗转换为德谷胰岛素利拉鲁肽注射液(Insulin Degludec and Liraglutide Injection,IDegLira)治疗方案的病例特征:4例糖尿病病程虽然均较长(≥8年),但空腹C肽水平仍大致正常,基础-餐时胰岛素多次注射方案经过剂量优化后血糖控制仍较差,提示胰岛素分泌相对不足和胰岛素抵抗同时存在。本组病例的经验分享旨在起到抛砖引玉的作用,希望更多临床医生关注中国2型糖尿病人群胰岛素泵转换为IDegLira的有效性、安全性及可行性,进一步积累临床应用经验,并且开展相关的临床研究。This article retrospectively summarized the 4 cases of type 2 diabetes(T2DM)who were switched from intensive insulin treatment with insulin pump to Insulin Degludec and Liraglutide Injection(IDegLira)in the department of endocrinology,the First Affiliated Hospital of Harbin Medical University.Although the duration of diabetes was long(more than 8 years),the fasting C-peptide level still remained generally normal with poor the blood glucose controlling after the dose optimization of the basal-bolus strategy.It suggested that relatively insufficient insulin secretion was accompanied by insulin resistance.This case sharing was intended to attract valuable discussion and suggestion.It is expected that more clinicians will pay attention to the effectiveness,safety and feasibility of the switch from insulin pump to IDegLira in Chinese T2DM population,further gather experience on clinical application,and promote relevant clinical research.

关 键 词：糖尿病 2型 胰岛素泵 德谷胰岛素利拉鲁肽注射液 病例报告 

分 类 号：R977.15[医药卫生—药品]